Came under criticism for disability and coronavirus paper
President-Elect Joe Biden announced soon after the election that University of Pennsylvania Prof. Ezekiel Emanuel would serve on his coronavirus task force.
The oncologist chairs Penn’s ethics and health policy department and co-authored a paper in April that argued for treating people with disabilities differently in coronavirus care based of their life expectancy.
He has previously written in support of healthcare rationing and urged 75-year-olds to stop pursuing primary care. Emanuel advised President Obama on healthcare policy as well.
The College Fix reached out to six different professors for comment on Emanuel’s appointment to the COVID-19 Transition Advisory Board and to see what principles they wanted to see Biden implement with regard to coronavirus policy. Only one professor responded to the inquiries.
Could cutting or delaying doses of the COVID-19 vaccine to immunize more people make the pandemic last longer?
inquirer.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from inquirer.com Daily Mail and Mail on Sunday newspapers.
email article
The group led by three physicians with a knack for making headlines posted its own review and meta-analysis of the global ivermectin literature on its website.
They maintain that ivermectin has a special combination of anti-viral and anti-inflammatory properties that make it useful preventively and for treating early and late-stage illness.
Too good to be true? Not in the mind of FLCCC co-leader Paul Marik, MD, chief of pulmonary and critical care medicine at Eastern Virginia Medical School in Norfolk, who co-authored the review and meta-analysis based mainly on studies from outside the U.S. People are dying, Marik said during a phone interview. We treat patients at the bedside. We don t have the ivory tower syndrome where you tell people what to do though you have no idea what you re doing.
The Downside to Getting Out Two COVID Vaccines So Fast Kaiser Health News
By Arthur Allen, KHN
As I prepared to get my shot in mid-December as part of a COVID-19 vaccine trial run by Janssen Pharmaceuticals, I considered the escape routes. Bailing out of the trial was a very real consideration since two other vaccines, made by Moderna and Pfizer-BioNTech, had been deemed safe and effective for emergency approval.
Leaving the trial would be a perfectly sane decision for me or anyone who had volunteered for an ongoing COVID experiment. Why risk getting COVID if I was given a placebo, a shot with no vaccine in it? The way tests are designed, I might not be told whether I received the vaccine until the clinical trial is over, months from now.
CAMBRIDGE, Mass. Americans will soon have access to a second COVID-19 vaccine.
Stephen Hahn, commissioner of the U.S. Food and Drug Administration, granted emergency authorization Friday to a vaccine made by Moderna, a week after giving similar clearance to one made by Pfizer and its German collaborator, BioNTech.
His is authorizing rather than approving the vaccine, because longer-term research is needed to meet the full standards for approval, which officials don t want to wait for during the public health emergency.
The speedy path to authorization was possible because the agency “cut through regulatory red tape,” Hahn said at a Friday night press conference. We worked quickly based on the urgency of this global pandemic . we have not cut corners.
vimarsana © 2020. All Rights Reserved.